MARKET WIREYahoo Finance • 9h ago
USANA (USNA) Q3 earnings report preview: what to look forYahoo Finance report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
Why USNA Stock slipped -0.21% Today — RQD Quant Desk Flash
$14.31 -0.21% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $14.28
USANA Health Sciences Inc. (USNA) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $265.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on USNA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is USNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, USANA Health Sciences Inc. (NYSE: USNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $14.31 (-0.21% 1D, market cap $265.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, USNA ranks #295 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does USNA compare to ACB and CGC in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), USNA carries a Roarable D (50/100 RQD), trailing P/E of 24.6x, gross margin of 78.3%, and ROIC of 7.9%. By comparison, ACB (Aurora Cannabis Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $252.8M) and CGC (Canopy Growth Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $285.6M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for USNA?
▼
Per USNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0000896264), USANA Health Sciences Inc. generated $925.3M in revenue (+8.3% YoY), $10.8M in net income, and $8.5M in free cash flow against $742.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $14.28 (-0.23%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for USNA)Realized 20D OHLCV Swing Band: ±8.8%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY USNA SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (28% of score)
Altman Z-Score 3.56 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (26% of score)
SEC Form 4 / 13F Thermometer: 65% Net Buy • Cannibal Buyback (-1.52% YoY Shares)
▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)
Macro rate sensitivity & RSI-14 (45.8) create a -15 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$14.95-0.4% Next Q
58
Q2 (-2Q)Grade C$14.89-5.7% Next Q
55
Q3 (-1Q)Grade C-$14.04+1.9% Next Q
53
CurrentGrade D$14.31-1.4% Hist 90D α
50
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a USNA Turnaround Squeeze
While USNA currently carries a cautious 50/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.57) and Max Pain ($15.03) forces dealer call-delta covering toward $24.77.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $USNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “USNA Beats Next Quarter EPS Consensus (Jan 2, 2027) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why USNA Stock slipped -0.21% Today — RQD Quant Desk Flash
USANA Health Sciences Inc. (USNA) slipped -0.21% to $14.31, trading at 16% of its 52-week range ($12.57 – $23.59). Stretched risk/reward at 25x P/E (8% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($12.57 – $23.59) with RSI-14 at 45.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.8% around $14.31 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 78.3% gross margin and $8.5M annual free cash flow.
Live USNA Headlines & Catalysts
MARKET WIREMarketBeat • 12h ago
USANA Health Sciences (USNA) Set to Release Quarterly Earnings on TuesdayMarketBeat report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 15h ago
Price-Driven Insight from (USNA) for Rule-Based StrategyStock Traders Daily report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 18h ago
USANA schedules third-quarter results for USANA Health Sciences stockad-hoc-news.de report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 21h ago
Why (USNA) Price Action Is Critical for Tactical TradingStock Traders Daily report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 1d ago
Zacks upgrades USANA Health Sciences stock from strong sell to holdad-hoc-news.de report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 13h ago
As Thanksgiving Nears, USANA CEO Kevin Guest Urges All to Rethink What Success Really MeansAs millions of people prepare to reconnect with family and friends during the Thanksgiving holiday season, USANA Health Sciences (NYSE: USNA) Chairman and CEO Kevin Guest is encouraging people to reconsider how they meas
MARKET WIREYahoo • 21d ago
USANA Schedules Third Quarter 2026 Earnings Release and Conference CallSALT LAKE CITY, October 12, 2026--USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2026 results will be released after the close of market on Tuesday, November 3, 2026. Shortly following the iss
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring USNA)
- ✓Walkthrough of USNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
USNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.90%🛡️ HOLDING TREND SUPPORT
2026-11-02O $14.62H $14.62L $14.31C $14.31VOL 129.6K
RES: $26.74SUP: $13.72SMA50: $14.57SMA200: $18.07
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
USNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
18.3%/yr Implied 5Y Growth
vs. +8.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on USNA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for USNA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for USNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (USNA)
Health Care Rank #295 of 1016
⚔️ ACB vs USNA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (USNA vs. ACB, CGC, SNDL, GLAS)
Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, USANA Health Sciences Inc. (USNA) ranks #295 by composite RQD confidence (50/100, grade D) and #535 by equity capitalization ($265.0M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. ACB currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with USNA at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| USNA
ACTIVE
USANA Health Sciences Inc. | D | 50/100 | 24.6x | 78.3% | 7.9% | -0.21% | $265.0M | Benchmark Subject |
| ACB Aurora Cannabis Inc. | D+ | 54/100 | — | — | — | -0.49% | $252.8M | /acb-vs-usna → |
| CGC Canopy Growth Corporation | D- | 41/100 | — | — | — | -3.33% | $285.6M | /cgc-vs-usna → |
| SNDL SNDL Inc. | D | 48/100 | — | — | — | -4.61% | $316.3M | /sndl-vs-usna → |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | E | 18/100 | — | 42.3% | -9.2% | -4.39% | $200.6M | /glas-vs-usna → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-01-03 • CIK 0000896264In its most recent audited fiscal period (FY2025, filed 2026-01-03), USANA Health Sciences Inc. (USNA) reported GAAP revenue of $925.3M (+8.3% vs. FY2024 revenue of $854.5M , and +0.5% cumulative change since FY2023) , GAAP net income of $10.8M, operating cash flow of $22.3M, and free cash flow of $8.5M (-83.3% YoY). On the balance sheet, USNA closed FY2025 with $742.9M in total assets against $0 in total debt (Altman Z-Score: 3.56, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-01-03 | $925.3M | $10.8M | $22.3M | $8.5M | $742.9M | — |
| FY2024 (FY) | 2024-12-28 | $854.5M | $42.0M | $61.0M | $50.9M | $748.2M | — |
| FY2023 (FY) | 2023-12-30 | $921.0M | $63.8M | $70.6M | $70.6M | — | — |
3. USNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs USNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, USANA Health Sciences Inc. (NYSE: USNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $14.31 (-0.21% 1D, market cap $265.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, USNA ranks #295 in composite RQD confidence.
How does USNA compare to ACB and CGC in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), USNA carries a Roarable D (50/100 RQD), trailing P/E of 24.6x, gross margin of 78.3%, and ROIC of 7.9%. By comparison, ACB (Aurora Cannabis Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $252.8M) and CGC (Canopy Growth Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $285.6M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for USNA?
Per USNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0000896264), USANA Health Sciences Inc. generated $925.3M in revenue (+8.3% YoY), $10.8M in net income, and $8.5M in free cash flow against $742.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is USNA trading relative to its 50-day, 200-day, and 52-week technical levels?
USNA last traded at $14.31 (-0.21% on volume of 141,035 shares), positioning the stock -1.78% below its 50-day simple moving average ($14.57) and -20.81% below its 200-day simple moving average ($18.07). Across its 52-week range of $12.57 to $23.59, USNA sits at the 15.8% percentile with a 14-day RSI of 45.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.8% ($13.05 to $15.57).
USNA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is USNA stock moving today?
Why USNA Stock slipped -0.21% Today — RQD Quant Desk Flash. Stretched risk/reward at 25x P/E (8% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 50/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
USNA — USANA Health Sciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:39:37Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, USNA scores 50 out of 100, a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 12/20 (ROIC 7.9%; FCF yield 3.22%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 13/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 14/20 (Altman Z 3.56; Piotroski F 7/9; Debt/Equity 0.5).
For a prospective investor, the pattern is a company with a sound balance sheet and moderate cash generation that is being scored down on institutional flow and macro/sector sensitivity. The strongest pillar is the forensic balance sheet; the weakest is macro regime fit, where a beta of 1.0 matches the market but the sector sensitivity assessment is low. The whale-flow pillar at 6/20 indicates weak institutional accumulation signals. Upside drivers would need to come from improved cash conversion and institutional re-accumulation; the valuation tradeoff is that the stock trades at a P/E (TTM) of 24.6 against a much lower EV/EBITDA of 2.7, a divergence an investor should reconcile against the reported earnings trend below. This is educational analysis, not personalized advice.
Snapshot
Business
USANA Health Sciences Inc. is a NYSE-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry. Per the Profile, the company operates in this industry with a market capitalization of $0.3B. Source data does not describe its specific products, customers, or revenue model beyond the sector and industry classification.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $925.3M | $37.4M | $10.8M | N/A | $8.5M | $158.4M | N/A |
| FY 2024 | $854.5M | $66.3M | $42.0M | N/A | $50.9M | $181.8M | N/A |
| FY 2023 | $921.0M | $93.1M | $63.8M | N/A | $70.6M | N/A | N/A |
Per the SEC financials, revenue moved from $921.0M (FY 2023) to $854.5M (FY 2024) before recovering to $925.3M (FY 2025), while net income declined from $63.8M to $10.8M across the same span. Current market data shows a gross margin of 78.3%, an operating margin of 4%, and a net margin of 1.2%, with ROIC at 7.9%. Per the Roarable RQD rating, the Altman Z-Score is 3.56, the Piotroski F-Score is 7/9, and Debt/Equity is 0.5, indicating a balance sheet the rating treats as a relative strength.
Recent Catalysts & News Wire Analysis
Per the recent news section, the wire contains six items, all tied to USNA. Catalysts flagged include an upcoming quarterly earnings release (reported as a preview of Q3 results and a Tuesday release date), a Zacks rating change from strong sell to hold, and a price-action commentary piece. Five items carry a YELLOW light and one carries a GREEN light, the latter being the Zacks upgrade. Risk watch items are limited to the earnings event itself, since the wire contains no detailed financial disclosures. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are the specific product lines and customer channels behind the $925.3M FY 2025 revenue?
- What drove the drop in net income from $63.8M (FY 2023) to $10.8M (FY 2025), and is it cyclical or structural?
- What is the EPS and debt figure behind the reported Debt/Equity of 0.5, given EPS and Debt are missing from the financial table?
- Why does a P/E of 24.6 coexist with an EV/EBITDA of 2.7, and which earnings base is the source using?
- What do the upcoming quarterly results need to show to shift the whale-flow and insider-conviction pillars?
USNA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for USANA Health Sciences Inc. (USNA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 9h ago
USANA (USNA) Q3 earnings report preview: what to look for Yahoo Finance report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 12h ago
USANA Health Sciences (USNA) Set to Release Quarterly Earnings on Tuesday MarketBeat report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 15h ago
Price-Driven Insight from (USNA) for Rule-Based Strategy Stock Traders Daily report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 18h ago
USANA schedules third-quarter results for USANA Health Sciences stock ad-hoc-news.de report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 21h ago
Why (USNA) Price Action Is Critical for Tactical Trading Stock Traders Daily report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 1d ago
Zacks upgrades USANA Health Sciences stock from strong sell to hold ad-hoc-news.de report covering USANA Health Sciences Inc. (USNA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 13h ago
As Thanksgiving Nears, USANA CEO Kevin Guest Urges All to Rethink What Success Really Means As millions of people prepare to reconnect with family and friends during the Thanksgiving holiday season, USANA Health Sciences (NYSE: USNA) Chairman and CEO Kevin Guest is encouraging people to reconsider how they meas
🟡 MARKET WIRE Yahoo • 21d ago
USANA Schedules Third Quarter 2026 Earnings Release and Conference Call SALT LAKE CITY, October 12, 2026--USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2026 results will be released after the close of market on Tuesday, November 3, 2026. Shortly following the iss
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
USNA Bull vs. Bear Conversation Board — What's Your Call at $14.31?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON USNA 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $15.49 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is USNA (D • RQD 50/100) a Buy at $14.34?
Welcome to the USNA (USANA Health Sciences Inc.) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $11.19 (-22.0%)
Spot @ $14.34 Pump the brakes on USNA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on USNA, but look at what you are paying: 24.6x trailing P/E with 78.3% gross margins. Unless USANA Health Sciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $17.93 (+25.0%)
Spot @ $14.34 USNA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on USNA, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $14.34 (52-wk range $12.57 - $23.59), any beat on forward guidance forces shorts and underweight funds to chase.